Eyepoint Pharmaceuticals reported Q3 2026 financial results and highlighted progress in its clinical development program, keeping focus on its ophthalmology pip

BWB News TV • 2026-11-12 13:12 UTC • By Billy Odell Tucker-Robinson

Eyepoint Pharmaceuticals reported Q3 2026 financial results and highlighted progress in its clinical development program, keeping focus on its ophthalmology pipeline after earlier Phase 3 LUCIA topline data for DURAVYU in wet AMD.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly